PHYSICIANS

Background

Dr. Muhsen is a full-time General surgeon at Clemenceau Medical Center, Beirut – Lebanon.

- She completed her surgical training at the American University of Beirut Medical Center in 2016.

- She completed a Breast Surgical Oncology fellowship (2016-2017) and a Colorectal Oncology fellowship at Memorial Sloan Kettering Cancer Center, New York – USA before returning back to Lebanon and joining CMC.

Titles

-General Surgeon – Clemenceau Medical Center, Beirut – Lebanon
-Director of the Surgery Residency Program – Clemenceau Medical Center, Beirut - Lebanon
 

Degrees

- Colorectal Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center  – New York, USA (2017-2018)
- Breast Surgical Oncology Fellowship at Memorial Sloan Kettering Cancer Center – New York, USA (2016-2017)
- General Surgery Residency at the American University of Beirut Medical Center – Beirut, Lebanon (2011-2016)
- Breast Surgical Oncology Research Fellowship at Memorial Sloan Kettering Cancer Center – New York, USA (2009-2011)
- Doctor of Medicine at the American University of Beirut – Beirut, Lebanon (2005-2009)
- Bachelor of Science at the American University of Beirut – Beirut, Lebanon (2002-2005)
 

Research

1. Journal Articles

- King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M. Is there a low-grade precursor pathway in breast cancer? Ann Surg Oncol 2012;19(4):1115-21.
- Hussein M, Issa G, Muhsen S, Haydar A. Superior mesenteric arteriovenous fistula embolisation complicated by bowel ischaemia. BMJ Case Rep 2013;2013.
- King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat 2013;142(2):445-53.
- Andrade VP, Morrogh M, Qin LX, Olvera N, Giri D, Muhsen S, Sakr RA, Schizas M, Ng CK, Arroyo CD, Brogi E, Viale A, Morrow M, Reis-Filho JS, King TA. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol 2015;9(4):772-82.
- King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol 2015;33(33):3945-52.
- De Brot M, Koslow Mautner S, Muhsen S, Andrade VP, Mamtani A, Murray M, Giri D, Sakr RA, Brogi E, King TA. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat 2017;165(2):411-20.
- Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Ann Surg Oncol. 2017;24(10):2889-2897.
- Muhsen S, Barrio AV, Miller M, Olcese C, Patil S, Morrow M, Van Zee KJ. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Ann Surg Oncol 2017;24(13):3888-95.
- Muhsen S, Moo TA, Patil S. Stempel M, Powell S, Morrow M, El-Tamer M. Most breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes do not need post mastectomy radiotherapy. Ann Surg Oncol. 2018 Jul;25(7):1912-1920.
- Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? Ann Surg Oncol. 2019 Feb;26(2):336-342

2.Oral Presentations

- Muhsen S, Morrogh M, Andrade VP, Sakr R, Paik W, Morrow M, King TA. Risk for subsequent breast cancer after lobular carcinoma in situ - do clinical factors matter? American Society of Clinical Oncology Annual Meeting, Chicago, IL. 2010
- Miller M, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer (CBC) Risk in Women with Ductal Carcinoma In Situ (DCIS): Is It High Enough to Justify Bilateral Mastectomy? 18th Annual Meeting of the American Society of Breast Surgeons, Las Vegas, NV, 2017

3. Abstracts
- Sakr RA, Chandarlapaty S, Barbashina V, Andrade VP, Morrogh M, Heguy A, Paik W, Arroyo CD, Olvera N, Patil S, Muhsen S, Rosen N, Morrow M, King T. Reduced/Absent PTEN Expression is more common in HER2 non-amplified DCIS. San Antonio Breast Cancer Symposium, San Antonio, TX, 2009
- Sakr R, Chandarlapaty S, Andrade V, Giri D, Muhsen S, Paik W, Morrow M, Rosen N, King T. PI3K mutations are more common in low grade DCIS. San Antonio Breast Cancer Symposium, San Antonio, TX, 2010
- Andrade VP, Morrogh M, Qin LX, Olvera N, Giri D, Brogi E, Alcantara-Filho P, Paik W, Muhsen S, Morrow M, King TA. Gene expression profiling identifies potential precursor genes in lobular carcinoma in situ. San Antonio Breast Cancer Symposium, San Antonio, TX, 2010
- Andrade VP, Morrogh M, Giri D, Qin LX, Sakr R, Olvera N, Paik W, Muhsen S, Brogi E, Morrow M, King TA. Gene expression profiling identifies two stable clusters of lobular carcinoma in situ. American Association for Cancer Research, Washington DC, 2010
- Sakr R, Chandarlapaty S, Barbashina V, Andrade V, Heguy A, Morrogh M, Olvera N, Paik W, Arroyo C, Muhsen S, Morrow M, Rosen N and King T. Alternate mechanisms of PI3K pathway activation among subtypes of ductal carcinoma in situ suggest distinct pathways for progression to invasive disease. American Association for Cancer Research, Washington DC, 2010
- Sakr R, Andrade VP, Muhsen S, Chandarlapaty S, Olvera N, Paik W, Giri D, Goldberg J, Van Zee KJ, Rosen N, Morrow M, King TA. Can PI3K/AKT pathway mutations predict for type of recurrence after conservative treatment for DCIS? American Association for Cancer Research, Orlando, FL, 2011
- King TA, Muhsen S, Patil S, Morrogh M, Sakr R, Morrow M. Is there a role for routine screening MRI in women with LCIS? Society of Surgical Oncology Annual Meeting, San Antonio, TX, 2011
- Oskar S, Muhsen S, Sung J, Patil S, Morrogh M, Sakr R, Morrow M, King TA. Chemoprevention among women with Lobular Carcinoma in Situ Society of Surgical Oncology Annual Meeting, San Antonio, TX, 2011
- Muhsen S, Junqueira MJ, Park A, Sung JS, Patil S, Oskar S, Morrogh M, Morrow M, King TA. Patient characteristics associated with the decision to undergo bilateral prophylactic mastectomy for lobular carcinoma in situ. ASCO Breast Cancer Symposium, San Francisco, CA, 2011
- Junqueira M, Eaton A, Muhsen S, Koss K, Stempel M, Patil S, Morrow M. Stage and presentation of first breast cancer are associated with stage and presentation of metachronous breast cancer. American Society of Breast Surgeons Annual Meeting, Phoenix, AZ, 2012
- Koslow S, Manschreck C, Patil S, Vijai J, Muhsen S, Park A, Robson M, King TA. Common breast cancer risk alleles and lobular carcinoma in situ (LCIS). 65th Annual Cancer Symposium of the Society of Surgical Oncology, Orlando, FL, 2012
- Sakr RA, Andrade VP, Chandarlapaty S, Giovanni C, Giri D, Heguy A, De Brot M, Olvera N, Muhsen S, Koslow S, Van Zee KJ, Morrow M, Rosen N, King TA. Molecular predictors for type of recurrence following conservative treatment for DCIS. San Antonio Breast Cancer Symposium, San Antonio, TX, 2012
- De Brot M, Muhsen S, Andrade VP, Mautner SK, Murray M, Giri D, Sakr R, Brogi E, King TA. Pleomorphic lobular carcinoma in situ: A distinct entity of controversial significance. Breast Cancer Symposium, San Francisco, CA, 2012
- Muhsen S, Barrio A, Olcese C, Patil S, Morrow M, Van Zee KJ. Outcomes of Women with Minimal Volume Ductal Carcinoma In Situ Completely Excised on Core Biopsy. Society of Surgical Oncology Annual Cancer Symposium, Seattle, WA, 2017
- Muhsen S, Patil S, Stempel M, Powell S, Morrow M, El-Tamer M. Most Breast Cancer Patients with T1-2 Tumors and 1-3 Positive Lymph Nodes Do Not Need Post-Mastectomy Radiotherapy. Society of Surgical Oncology Annual Cancer Symposium, Seattle, WA, 2017
- Gemignani M, Muhsen S. Characteristics and Choices of Young Women with Breast Cancer Referred to a Fertility Nurse Specialist Program. 18th Annual Meeting of the American Society of Breast Surgeons, Las Vegas, NV, 2017
- Muhsen S, Dang C, Plitas G, Seier K, Stempel M, Patil S, Morrow M, El-Tamer M. Chemotherapy with and without trastuzumab or no treatment in elderly patients with HER2 amplified breast cancer at a single center. San Antonio Breast Cancer Symposium, San Antonio, TX, 2017
- Muhsen S, Dang C, Plitas G, Knezevic A, Stempel M, Patil S, Morrow M, El-Tamer M. Frequency of delivery of systemic chemotherapy in elderly versus younger patients with triple negative breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2017
- Baker J, Muhsen S, Zabor E, Stempel M, Gemignani ML. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? Accepted for poster presentation at the 71st Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, 2018
- Muhsen S, Moo TA, Zabor E, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini VS. Increase in Utilization of Nipple Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. Accepted for poster presentation at the 71st Society of Surgical Oncology Annual Cancer Symposium, Chicago, IL, 2018
- Muhsen S, Moo TA, Zabor E, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini VS. Prophylactic Nipple- Sparing Mastectomy: Indications, Complications, and Oncologic Outcomes. Accepted for poster presentation at the 19th Annual Meeting of the American Society of Breast Surgeons, Orlando, FL, 2018
- Miller ME, Muhsen S, Zabr EC, Flynn J, Olcese C, Giri D, Van Zee KJ, Pilewskie. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma in Situ. Accepted for poster presentation at the San Antonio Breast Cancer Symposium, San Antonio, TX, 2018

4. Research Awards
- Lynn Sage Symposium Scholar Award, 18th Annual Lynn Sage Breast Cancer Symposium, Chicago, Illinois (2016)
- Clinical Poster Award, 70th Annual Cancer Symposium of the Society of Surgical Oncology, Seattle Washington (2017)